Daiwa Securities Group Inc. Boosts Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Daiwa Securities Group Inc. raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 34.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 11,798 shares of the company’s stock after purchasing an additional 2,997 shares during the period. Daiwa Securities Group Inc.’s holdings in Neurocrine Biosciences were worth $1,360,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in NBIX. 1832 Asset Management L.P. increased its holdings in Neurocrine Biosciences by 1,370.7% during the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock valued at $74,507,000 after acquiring an additional 504,400 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Neurocrine Biosciences by 639.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after purchasing an additional 363,863 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Neurocrine Biosciences by 23.0% during the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after purchasing an additional 228,444 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Neurocrine Biosciences by 9.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock worth $339,790,000 after purchasing an additional 216,500 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Neurocrine Biosciences by 40.3% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock worth $97,828,000 after purchasing an additional 203,934 shares during the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on NBIX. Oppenheimer raised their price target on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Guggenheim raised their price target on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Robert W. Baird raised their price target on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Barclays decreased their price target on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Finally, Citigroup raised their target price on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Stock Up 0.1 %

NBIX opened at $126.75 on Friday. The firm has a market capitalization of $12.83 billion, a P/E ratio of 33.98 and a beta of 0.35. The firm’s 50 day moving average is $119.26 and its 200-day moving average is $131.61. Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.